ISSN 0976 - 8157

Indexing & Abstracting: DOAJ, Index Copernicus, Chemical Abstract Services (CAS), EBSCO Publishing, Ulrich's Serial database, NewJour, GFMER, Science Central, Libraries Directory, IRNEM, Biblioteca, Open J-gate...........
Home News

FDA grants orphan drug status to RiVax

The US Food and Drug Administration (FDA)has given orphan drug status to Soligenix's ricin intoxication preventive, RiVax. Soligenix has completed a Phase 1A clinical trial of RiVax which showed that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. Further, the company is continuing Phase 1B trial of RiVax. Soligenix president and CEO Christopher Schaber said the FDA's decision to grant RiVax orphan drug designation for the prevention of ricin intoxication marks another important step forward in their biodefense pipeline.

"Marketing exclusivity through orphan drug designation adds significantly to the existing patent estate surrounding RiVax," Schaber said.




Editorial Board

Who's Online

We have 24 guests online

Statistics Counter

joomla visitor


Do you think pharmaceutical companies should spend more on educating physicians about their products?

Social Widgets